B.C. approves coverage of HIV-blocking drug for high-risk groups

Activists are applauding the B.C. government for approving coverage of an HIV-prevention drug for those at high-risk of infection.

On Thursday, the Ministry of Health announced that access to pre-exposure prophylaxis – better known as PrEP – will be free of charge beginning Jan. 1 for men and transwomen who have sex with men, injection drug users and people who have sex with HIV-positive people.

Sold under the brand name Truvada, the drug was approved by Health Canada last year and can be prescribed as both a treatment for people with the disease, as well as a preventative therapy to keep people at high risk from contracting the virus.

“Making this medication free for people will prevent new HIV infections, remove barriers to care and services and help people live longer and healthier lives,” said Health Minister Adrian Dix in a statement.

PrEP is recommended as a preventative measure by the World Health Organization and the BC Centre for Excellence in HIV/AIDS.

Some studies have found it can cut the risk of HIV infection by up to 90 per cent if taken before or after sex.

Managing director of the Community Based Research Centre (CBRC) Jody Jollimore said the news once again positions B.C. as an HIV prevention leader.

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)